Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
STAT   2 days ago
ads
Read Full Story
Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda  statnews.comAkeso and Summit notch another Phase III win with their Keytruda competitor  Yahoo FinanceWith new trial win, Akeso bispecific shows prior success against...